Skip to content

    Cancer Clinical Trials

    A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (TroFuse-021)

    Learn more

    What is the purpose of this study?

    Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

    Eligibility

    The main inclusion criteria include but are not limited to the following:

    • Has diagnosis of FIGO 2014 Stage III or Stage IV, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with one of the following histologies: high-grade serous, high-grade endometrioid, clear cell carcinoma, or malignant mixed Müllerian tumour with a high-grade serous component. Tumors reported as Grade 2 may be enrolled only if predominately (>50%) Grade 3 features are present.
    • Has completed primary debulking surgery or interval debulking surgery.
    • Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol.
    • Has provided tumor tissue that is not previously irradiated.
    • Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if diagnosed with HIV
    • Has undetectable hepatitis B virus (HBV) viral load and received HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.
    • Has undetectable hepatitis C virus (HCV) viral load if has a history of HCV infection.

    The main

    Where can I participate?

    Hoag Hospital Irvine
    16200 Sand Canyon Ave
    Irvine, CA 92618


    Lauren Wagner

    lauren.wagner@hoag.org


    Hoag Hospital Newport Beach
    1 Hoag Dr
    Newport Beach, CA 92663


    Lauren Wagner

    lauren.wagner@hoag.org


    More about this Clinical Trial

    What is the full name of this Clinical Trial?

    A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

    • Disease Type/ConditionOvarian Neoplasms, Ovarian Cancer
    • Principal InvestigatorTiffany L. Beck, MD
    • Co-InvestigatorsAlbert Mendivil, Lisa Abaid, John Brown, Monica Levine, Antonio Casteneda, Naz anvari, Andrea Beatty
    • Age GroupAdult, Older Adult
    • PhaseIII
    • ClinicalTrials.gov IDNCT07318558

    Hoag Family Cancer Institute

    Hoag Family Cancer Institute delivers advanced, compassionate cancer care across Orange County, with multidisciplinary specialists, precision therapies, support services, and access to 125+ cancer clinical trials. Patients benefit from research-driven care across a wide range of cancers, including breast, lung, gynecologic, prostate, gastrointestinal, and blood cancers.

    Learn More
    Dr. Grossman in a white coat writing on a board

    Stay up-to-date on the latest news from Hoag

    By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.